SEC For	m 4																
FORM 4 UNITED STA					TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB APPROVAL			
Check this box if no longer subject to SECTION 16. Form 4 or Form 5 obligations may continue. See					IT OF CHANGES IN BENEFICIAL OWNERSHIP									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940																0.0	
1. Name and Address of Reporting Person* SARGEN GREGORY						2. Issuer Name and Ticker or Trading Symbol Protara Therapeutics, Inc. [ TARA ]								g Pers	son(s) to Iss 10% Ov		
(Last) C/O PRC	(Last) (First) ( C/O PROTARA THERAPEUTICS,				3. Date of Earliest Transaction (Month/Day/Year) 06/09/2020								or (give title	ve title Other (specif below)			
1 LITTL	E WEST	12TH STREET		4.	If Amer	ndment,	Date	of Original Fi	led (Month/D		6. Individual or Joint/Group Filing (Check Applicable						
(Street) NEW YORK NY			10014									iled by More	One Reporting Person More than One Reporting				
(City)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transau Date (Month/Date)					ear) E	A. Deem xecution any Month/D	n Date	Code (In:	ion Dispose	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		Benefici Owned	es Forr ally (D) of Following (I) (I		r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code \	/ Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversic or Exercis Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans Code	action	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/	cisable and ate	1		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$35	06/09/2020		A		9,000		(1)	06/08/2030	Common Stock	9,000	\$0.00	9,000		D		

## Explanation of Responses:

1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

## Remarks:

## /s/ Jesse Shefferman, Attorneyin-fact 06/10/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.